Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investment in QuantaSol

28 Jun 2007 07:02

Imperial Innovations Group plc28 June 2007 28 June 2007 Imperial Innovations Group plc ("Imperial Innovations") Investment in QuantaSol Limited Imperial Innovations Group plc, the technology commercialisation and investmentcompany (AIM: IVO) today announces that a £1.35 million investment round intoQuantasol has closed. As part of this round Imperial Innovations has invested£300,000 on a milestone basis in QuantaSol Limited (QuantaSol), a developer ofphotovoltaics (PV) - solar power technology that converts sunlight directly toelectricity. The round also included significant funding from Low CarbonAccelerator, NetScientific Ltd and Numis Corporation PLC. Following theinvestment, Imperial Innovations owns a 24% stake in the company. QuantaSol plans to provide solar photovoltaic cells for use in Concentrating PV(CPV) systems for the fast growing utility-scale solar power generation market.The company will use the funds to produce prototypes of its Quantum WellPhotovoltaic (QWPV) cells and to engage with potential customers for these solarPV cells. CPV systems use relatively inexpensive optics such as mirrors or lenses toconcentrate or focus light from a broad collection area onto a much smaller areaof active semiconductor PV cell material. Since the PV semiconductor materialusually dominates the costs of a solar PV system, reducing the amount of PVmaterial required to capture a given amount of sunlight leads to substantiallylower system cost and cost per watt of output. QuantaSol's "third generation"cells are based on Gallium arsenide (GaAs) and other III-V semiconductormaterials. These materials are more expensive than silicon, which is commonlyused for flat panel PV, but have more than double the photovoltaic efficiency.QuantaSol plans to manufacture single and multi-junction concentrator solarcells with efficiency levels of up to 40%. QuantaSol was formed in 2006 and is based on the research of Professor KeithBarnham, Emeritus Professor of Physics and Senior Research Investigator in theDepartment of Physics at Imperial College London; Dr. Massimo Mazzer, SeniorResearcher of the National Research Council of Italy; and Dr. John Roberts,Senior Research Scientist at The University of Sheffield. The company also has astrong and experienced management team in place which includes CEO Kevin Arthurwho has twenty-three years of international business development and operationalexperience in semiconductor manufacturing companies and technology start-ups. Following the investment, the board of QuantaSol will be strengthened furtherwith the appointment of Oliver Hemsley, CEO of Numis Corporation PLC, as anon-executive director. Susan Searle, Chief Executive, Imperial Innovations, said, "QuantaSol'stechnology is derived from strong research by a team of world-class scientists.We are keen to support them through the early stages and will continue to workwith them as they develop the company and become a significant player in thesolar energy market." Kevin Arthur, Chief Executive, QuantaSol, said, " We are very grateful for thesupport that we have received from Imperial Innovations, and are looking forwardto working with them and the rest of the investor group to take QuantaSolforward to become a major global supplier of third generation, high efficiencysolar cells." -Ends- For more information contact: Imperial InnovationsSusan Searle, Chief Executive Officer +44 (0)20 7594 6591Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644 M:CommunicationsPatrick d'Ancona / Harriet Totty +44 (0)20 7153 1590 JP Morgan Cazenove +44(0)20 7588 2828Steve Baldwin Notes to Editors About Imperial InnovationsImperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £26 million. The company's integrated approach encompassesthe identification of ideas, protection of intellectual property, developmentand licensing of technology and formation, incubation and investment intechnology businesses. A wide range of technologies are commercialised withinthe areas of healthcare, energy, environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in70 technology businesses and has completed 116 commercial agreements. ImperialInnovations also commercialises technologies originating from outside ImperialCollege through incubation contracts with the Carbon Trust and WRAP and hasrelationships with a number of multinational corporations including BAE Systems. Imperial Innovations has invested in a range of spin-out companies, includingThe Acrobot Company Limited, BioCeramic Therapeutics Limited, Cardiak Limited,Circassia Holdings Limited, deltaDOT Limited, Equinox Pharma Limited, FutureWaves PTE Limited, HeliSwirl Technologies Limited, InforSense Limited, IXICOLimited, Lontra Limited, Midaz Lasers Limited, NanoBioDesign Limited, NexeonLimited, NovaThera Limited, Thiakis Limited and Veryan Medical Limited. Imperial Innovations currently holds shares in four technology businesses nowlisted on AIM including the fuel cell company, Ceres Power plc. www.imperialinnovations.co.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Jun 20177:00 amRNSForm 8 (OPD) IP Group PLC
6th Jun 201711:19 amRNSForm 8.3 - Touchstone Innovations
5th Jun 201712:46 pmRNSForm 8.3 - Touchstone Innovations Plc
1st Jun 20172:41 pmBUSForm 8.3 - Touchstone Innovations plc
1st Jun 20177:00 amRNSChairman's letter to shareholders
31st May 20175:58 pmRNSForm 8.5 (EPT/RI) - Touchstone Innovations Plc
31st May 201712:01 pmRNSForm 8.3 - Touchstone Innovations Plc
30th May 20177:00 amRNSForm 8.3 - Touchstone Innovations Plc
26th May 201712:29 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:15 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:14 pmRNSForm 8.3 - Touchstone Innovations Plc
25th May 201712:10 pmRNSForm 8.3 - IP Group Plc
24th May 20172:55 pmRNSForm 8.3 - IP Group plc
24th May 20172:52 pmRNSForm 8.3 - Touchstone Innovations plc
24th May 20172:51 pmRNSForm 8.3 - IP Group Plc
24th May 20172:41 pmRNSForm 8.3 - Touchstone Innovations Plc
24th May 20171:15 pmRNSForm 8.3 - Touchstone Innovations Plc
24th May 201711:17 amBUSForm 8 (DD) - Touchstone Innovations Plc.
23rd May 201712:05 pmRNSUpdate on possible offer
23rd May 201711:45 amRNSForm 8.3 - Touchstone Innovations Plc
23rd May 201710:33 amRNSStatement re Possible Offer
23rd May 20177:01 amRNSStatement re Possible Offer
21st Apr 201711:21 amRNSInnovations invests £2.9m in Abzena placing
6th Apr 20177:00 amRNSInnovations provides seed funding for Cardian
31st Mar 20177:00 amRNSHalf Yearly Report
20th Mar 20177:05 amRNSInnovations supports funding round in Pulmocide
16th Mar 20177:00 amRNSInnovations invests in Cell Medica funding round
14th Mar 20177:00 amRNSInnovations supports funding round in Resolver
6th Mar 20177:00 amRNSInnovations leads £12m funding round in Garrison
28th Feb 201711:11 amRNSNotice of Results
21st Feb 20177:03 amRNSCell Medica granted FDA Fast Track designation
26th Jan 20172:00 pmRNSDirectorate Change
5th Jan 20177:00 amRNSChange of name to Touchstone Innovations plc
4th Jan 20179:00 amRNSAppointment of Joint Broker
20th Dec 201612:03 pmRNSPsiOxus signs exclusive licence agreement with BMS
28th Nov 20167:02 amRNSPortfolio company TopiVert receives IND approval
23rd Nov 20165:56 pmRNSGrant of share options
21st Nov 201612:53 pmRNSResult of AGM
28th Oct 201612:30 pmRNSProposed change of name to Touchstone Innovations
28th Oct 201612:29 pmRNSPosting of Annual Report and Notice of AGM
24th Oct 20167:12 amRNSVeryan announces completion of subject enrolment
13th Oct 20167:00 amRNSFinal Results
10th Oct 20161:02 pmRNSCrescendo Biologics sign collaboration with Takeda
6th Oct 20167:02 amRNSFirst patients dosed in TopiVert's Phase IIa study
3rd Oct 201612:10 pmRNSSale of Innovations portfolio company Permasense
21st Sep 20167:06 amRNSInnovations invests £5.1m in Artios Pharma Limited
14th Sep 201612:02 pmRNSNotice of Results
13th Sep 20164:08 pmRNSTR-1: Notification of major interest in shares
9th Sep 20161:15 pmRNSHolding(s) in Company
6th Sep 20164:17 pmRNSEdison issues update on Imperial Innovations (IVO)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.